SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Dr. Reddy's Lab reports Profit after tax of Rs 11926.00 Mln, in the September 2023 quarter

27 Oct 2023 Evaluate
The revenue declined to Rs. 48387.00 millions for the quarter ended September 2023 as compared to Rs. 48803.00 millions during the corresponding quarter last year.The Company has registered profit of Rs. 11926.00  millions for the quarter ended September 2023, a growth of 6.84%  over Rs. 11163.00 millions millions achieved in the corresponding quarter of last year.A decline of 18522.00 millions was observed in the OP in the quarter ended September 2023 from 19208.00 millions on QoQ basis.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202309 202209 % Var 202309 202209 % Var 202303 202203 % Var
Sales 48387.00 48803.00 -0.85 102760.00 85109.00 20.74 169625.00 144052.00 17.75
Other Income 2231.00 1180.00 89.07 4567.00 5214.00 -12.41 5913.00 4820.00 22.68
PBIDT 18522.00 19208.00 -3.57 43135.00 29037.00 48.55 48061.00 30761.00 56.24
Interest 58.00 17.00 241.18 103.00 115.00 -10.43 169.00 380.00 -55.53
PBDT 18464.00 19191.00 -3.79 43032.00 28922.00 48.79 47892.00 30381.00 57.64
Depreciation 2458.00 2262.00 8.66 4830.00 4477.00 7.88 9232.00 8143.00 13.37
PBT 16006.00 16929.00 -5.45 38202.00 24445.00 56.28 38660.00 22238.00 73.85
TAX 4080.00 5766.00 -29.24 9882.00 8287.00 19.25 12532.00 6006.00 108.66
Deferred Tax 120.00 2790.00 -95.70 535.00 3953.00 -86.47 3891.00 2080.00 87.07
PAT 11926.00 11163.00 6.84 28320.00 16158.00 75.27 26128.00 16232.00 60.97
Equity 834.00 832.00 0.24 834.00 832.00 0.24 833.00 832.00 0.12
PBIDTM(%) 38.28 39.36 -2.74 41.98 34.12 23.04 28.33 21.35 32.69

Dr. Reddys Labs. Share Price

1210.85 -13.05 (-1.07%)
17-Jul-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1933.10
Dr. Reddys Labs. 1210.85
Cipla 1418.40
Lupin 2442.10
Zydus Lifesciences 1142.75
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: